Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529).
Tokito T, Yamada K, Ishii H, Takiguchi Y, Saito G, Minato K, Imai H, Tanaka H, Miura S, Watanabe K, Koreeda Y, Ono A, Furuya N, Misumi T, Hayakawa K, Ogo E, Okamoto H. Tokito T, et al. Among authors: misumi t. Radiat Oncol. 2025 Jan 4;20(1):2. doi: 10.1186/s13014-024-02577-5. Radiat Oncol. 2025. PMID: 39755666 Free PMC article. Clinical Trial.
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.
Akamatsu H, Koh Y, Nishio M, Goto Y, Hayashi H, Miura S, Tamada K, Kagamu H, Gemma A, Yoshino I, Misumi T, Mouri A, Saito R, Takase N, Yanagitani N, Nokihara H, Seike M, Takamura K, Mori M, Iwasawa S, Nakagawa S, Mitsudomi T. Akamatsu H, et al. Among authors: misumi t. Lung Cancer. 2024 Dec;198:108017. doi: 10.1016/j.lungcan.2024.108017. Epub 2024 Nov 9. Lung Cancer. 2024. PMID: 39571250 Free article.
Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study.
Toyota K, Tanabe K, Kano M, Komo T, Hotta R, Yanagawa S, Saeki Y, Tazawa H, Ikeda M, Shishida M, Okano K, Ide R, Imaoka Y, Takahashi S, Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Toyota K, et al. Gastric Cancer. 2025 Jan;28(1):102-111. doi: 10.1007/s10120-024-01563-w. Epub 2024 Nov 9. Gastric Cancer. 2025. PMID: 39520590 Free PMC article.
Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Hayashi H, Nishio M, Akamatsu H, Goto Y, Miura S, Gemma A, Yoshino I, Misumi T, Kijima T, Takase N, Fujita M, Tasaka S, Mouri A, Kondo T, Takamura K, Kawashima Y, Imaizumi K, Iwasawa S, Nakagawa S, Mitsudomi T. Hayashi H, et al. Among authors: misumi t. Cancer Res Commun. 2024 Nov 1;4(11):2858-2867. doi: 10.1158/2767-9764.CRC-24-0212. Cancer Res Commun. 2024. PMID: 39392339 Free PMC article.
Prognostic risk score and index including the platelet-to-lymphocyte ratio and lactate dehydrogenase in patients with metastatic or unresectable urothelial carcinoma treated with immune checkpoint inhibitors.
Kobayashi K, Sakano S, Matsumoto H, Yamamoto M, Tsuchida M, Tei Y, Nagao K, Oba K, Kitahara S, Yano S, Yoshihiro S, Yamamoto Y, Ohmi C, Komatsu H, Misumi T, Akao J, Shiraishi K. Kobayashi K, et al. Among authors: misumi t. Jpn J Clin Oncol. 2024 Oct 7:hyae137. doi: 10.1093/jjco/hyae137. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39373462
208 results